Recent Updates — LFWD
The Board of Directors appointed Ronen Tsimerman as Chief Financial Officer, principal financial officer and principal accounting officer, effective November 1, 2026. His employment agreement provides for a gross monthly base salary of NIS 70,000, an annual performance-based bonus with a target of not less than four monthly salaries, and a transaction bonus. The arrangement is subject to shareholder approval of the company's renewed compensation policy at its upcoming annual general meeting on October 30, 2026. Lifeward Ltd. operates in the medical technology sector.
Rami Aviram informed Lifeward Ltd. on October 4, 2026 that he will not join the company as Chief Financial Officer, principal financial officer, or principal accounting officer, reversing his appointment announced in August and October 2026. Interim CFO Josh Hexter continues to serve in these capacities without additional compensation while the company searches for a permanent successor. Lifeward Ltd. operates in the healthcare technology sector.
Lifeward Ltd. appointed Josh Hexter as interim principal financial officer and principal accounting officer effective October 1, 2026, following Almog Adar's departure on September 30, 2026. Hexter will serve in these roles until November 1, 2026, when Rami Aviram assumes the position of Chief Financial Officer. Hexter receives no additional compensation for this interim designation. Lifeward Ltd. operates in the healthcare technology industry, providing software solutions to improve patient care and operational efficiency.
Lifeward Ltd. announced that President and CEO Mark Grant departed effective August 31, 2026, following a separation agreement. His unvested equity awards were forfeited, and he will serve as Senior Advisor through September 30, 2026, for a $40,000 consulting fee without cash severance. The Board appointed Josh Hexter as Interim CEO effective September 1, 2026; Hexter receives a monthly salary of NIS 100,000 plus benefits and will reduce his role at controlling shareholder Oramed Pharmaceuticals to approximately 5% of his time. Additionally, Rami Aviram was appointed CFO effective November 1, 2026, succeeding Almog Adar who departs September 30, 2026; Aviram receives a monthly salary of NIS 70,000 plus benefits. Lifeward Ltd. operates in the life sciences industry, developing medical devices and treatments.